Company: ZVRA
Filing Date: 2025-05-08
Form Type: DEFA14A
Source: 0001193125-25-115961
Chunk: 1

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-08
Form: DEFA14A
Chunk 1
---
 objectives; our liquidity position; and the timing of any of the foregoing. These forward-looking statements are based on information currently available to Zevra and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors including those discussed under the caption “Risk Factors” in our Annual Report for the year ended December 31, 2024, on Form 10-K and filed with the Securities and Exchange Commission (SEC) on March 12, 2025, and in our other filings with the SEC could cause actual results, performance, or achievements to differ materially from those indicated by the forward-looking statements made herein. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to this presentation. This presentation also may contain estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Cautionary Note Regarding Forward-Looking Statements

Corporate Foundation: Strengthening Our Foundation Bolstered balance sheet by restructuring debt in April 2024, using new credit facility provided by premier biotech investors, providing ample financial flexibility to continue investing in growth Secured Rare Pediatric Disease Priority Review Voucher (PRV) with the approval of MIPLYFFA Sold PRV for $150 million in April 2025, providing non-dilutive capital to fuel commercial launches of MIPLYFFA and OLPRUVA® Pipeline and Innovation: Enhancing the Value of Our Pipeline and Driving Innovation Completed a comprehensive review of our development pipeline to facilitate investment in the most promising, highest return opportunities Launched Phase 3 DiSCOVER trial of celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS) Announced positive topline results from our KP1077 Phase 2 trial in idiopathic hypersomnia at the 2024 Annual SLEEP Meeting and